ClinicalTrials.gg
CompletedNCT03285568Updated Mar 31, 2023

Patterns of Prescribing and Monitoring of Palbociclib

An observational study in Metastatic Breast Cancer, Advanced Breast Cancer and Estrogen Receptor-positive Breast Cancer, sponsored by Rush University Medical Center. Completed. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-03-31.

Sponsored by Rush University Medical Center · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
67
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to determine if patients with ER+, human epidermal growth factor 2 negative (HER2-), advanced breast cancer are receiving dosing adjustments and monitoring based on manufacturer recommendations at a tertiary academic medical center.

Read the detailed description

This study was a retrospective, single-center study that included women receiving palbociclib for the treatment of ER+, HER2- advanced breast cancer. Exclusion criteria were the presence of brain metastases or active enrollment in a palbociclib clinical trial.

The primary endpoint was the proportion of patients who were maintained on a palbociclib dose according to the adjustment schedule in package insert recommendations.

The secondary endpoints were the number of patients dose adjusted for hematologic toxicities, the number of patients experiencing neutropenia, duration of therapy, progression-free survival (PFS), and adherence to manufacturer monitoring recommendations.

02

Conditions studied

  • Metastatic Breast Cancer
  • Advanced Breast Cancer
  • Estrogen Receptor-positive Breast Cancer
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Browse trials for

03

In context

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 67 is below the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Rush University Medical Center is the lead sponsor of 397 studies on the registry; 61 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients seen at RUMC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women at least 18 years old
  • ER+, - advanced breast cancer
  • receiving palbociclib

Exclusion criteria

Exclusion Criteria:

  • on palbociclib clinical trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
67 participants (actual)
Patient registry
No

Groups and cohorts

  • Palbociclib

    women at least 18 years old, with ER+, HER2- advanced breast cancer, and were receiving palbociclib

    Drug: Palbociclib

Interventions

  • Observe patients receiving palbociclib for dose adjustment and lab monitoring

    Also known as: IBRANCE

06

What researchers measure

Primary outcomes

  1. Palbociclib dose according to the package insert recommendations.

    Identify the proportion of patients who were maintained on a palbociclib dose according to the package insert recommendations.

    Time frame: 22 months

Secondary outcomes

  1. Dose adjustment for hematologic toxicities

    Number of patients who required dose adjustment for hematologic toxicities while on the study.

    Time frame: 22 months

  2. Number of patients who experienced neutropenia.

    Patients who experienced neutropenia as a result of their participation in the study.

    Time frame: 22 months

  3. Duration of therapy

    Number of patients who completed the study compared to the number of patients who were was discontinued with the most common reason for discontinuation being disease progression

    Time frame: 22 months

  4. Progression free survival (PFS)

    Progression free survival duration of patients that were in the study who received Palbociclib

    Time frame: 22 months

  5. Adherence to manufacturer monitoring recommendations

    Patient adherence was also a limitation of this study as providers relied on the patient report to track medication adherence. Insurance coverage and access to palbociclib also contributed some variability as there were occasional delays in initiation of therapy or change in dose.

    Time frame: 22 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Dec 2016, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2017
First posted
Sep 18, 2017
StartActual
Feb 3, 2015
Primary completionActual
Dec 30, 2016
CompletionActual
Dec 30, 2016
Last update
Mar 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03285568
Responsible party
Sponsor
First posted
Sep 18, 2017
Start date
Feb 3, 2015
Primary completion
Dec 30, 2016
Completion
Dec 30, 2016
Last update
Mar 31, 2023

Study contacts

Kathryn Schultz
principal investigator · Rush University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion